Changes of Prolactin Secretion Following Long-Term Danazol Application

H G Bohnet, Bohnet HG, J P Hanker, Hanker JP, Karl-Werner Schweppe, K W Schweppe, Schweppe KW, H P Schneider, H. P. G. Schneider, Schneider HP
Fertility and Sterility · 1981 · vol. 36(6) , pp. 725–728 · doi:10.1016/s0015-0282(16)45915-7 · PMID:6796443 · W2408790396
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This paper investigated alterations in prolactin secretion during extended danazol treatment in a patient.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Patients (n = 10) with endometriosis or fibrocystic mammary disease were treated with an oral dose of 4 x 200 mg danazol for 6 months. Prolactin and gonadotropin secretion was evaluated before, and in some of them during 1, 3, and 6 months of therapy, as well as 4 weeks after discontinuation of the steroid. Prolactin, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol, and progesterone were measured before a bolus of 10 mg metoclopramide and 25 micrograms LH-releasing hormone (LH-RH) had been given. The serum concentrations of prolactin and LH were estimated 25 minutes and those of FSH 45 minutes thereafter. Basal and stimulated serum prolactin levels, measured during the luteal phase of the control cycle preceding danazol application, decreased continuously, reaching serum concentrations seen during the early follicular phase of the cycle. This was paralleled by a decrease of estradiol and a lack of progesterone secretion. While basal and LH-RH-stimulated LH was practically unchanged, basal and stimulated FSH showed a significant increase. Within 4 weeks of discontinuation of the drug all hormonal parameters were similar to pretreatment values. The data presented may explain the beneficial effect of the drug on fibrocystic mammary disease, i.e., by the decrease of serum and pituitary prolactin. The selective increase of FSH secretion is unclear but may reflect the lack of negative feedback mechanisms of follicular inhibin.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Danazol Pregnadienes Prolactin Danazol Endometriosis Endometriosis Estradiol Estradiol Female Fibrocystic Breast Disease Fibrocystic Breast Disease Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Luteinizing Hormone Luteinizing Hormone Pituitary Gland Pituitary Gland Pregnadienes Progesterone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (10)

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:06.101301+00:00
License: CC0 · commercial use OK